Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 599

1.

[Prostate cancer: what treatment techniques for which tumors? Ethical and methodological issues].

de Crevoisier R, Castelli J, Guérif S, Pommier P, Créhange G, Chauvet B, Lagrange JL.

Cancer Radiother. 2014 Oct;18(5-6):369-78. doi: 10.1016/j.canrad.2014.07.154. Epub 2014 Sep 6. Review. French.

PMID:
25199865
[PubMed - indexed for MEDLINE]
2.

[Postoperative radiotherapy of prostate cancer].

Guérif S, Latorzeff I, Lagrange JL, Hennequin C, Supiot S, Garcia A, François P, Soulié M, Richaud P, Salomon L.

Cancer Radiother. 2014 Oct;18(5-6):517-23. doi: 10.1016/j.canrad.2014.07.149. Epub 2014 Sep 5. Review. French.

PMID:
25195116
[PubMed - indexed for MEDLINE]
3.

Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?

Créhange G, Roach M 3rd, Martin E, Cormier L, Peiffert D, Cochet A, Chapet O, Supiot S, Cosset JM, Bolla M, Chung HT.

Cancer Radiother. 2014 Oct;18(5-6):524-34. doi: 10.1016/j.canrad.2014.07.153. Epub 2014 Sep 2. Review. Erratum in: Cancer Radiother. 2014 Dec;18(8):806.

PMID:
25192626
[PubMed - indexed for MEDLINE]
4.

Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.

Lane JA, Donovan JL, Davis M, Walsh E, Dedman D, Down L, Turner EL, Mason MD, Metcalfe C, Peters TJ, Martin RM, Neal DE, Hamdy FC; ProtecT study group.

Lancet Oncol. 2014 Sep;15(10):1109-18. doi: 10.1016/S1470-2045(14)70361-4. Epub 2014 Aug 19. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475.

PMID:
25163905
[PubMed - indexed for MEDLINE]
Free Article
5.

[New methods in the treatment of localized prostate cancer: use of dynamic arc therapy and kV cone-beam CT positioning].

Szappanos S, Farkas R, Lőcsei Z, László Z, Kalincsák J, Bellyei S, Sebestyén Z, Csapó L, Sebestyén K, Halász J, Musch Z, Beöthe T, Farkas L, Mangel L.

Orv Hetil. 2014 Aug 10;155(32):1265-72. doi: 10.1556/OH.2014.29883. Hungarian.

PMID:
25087218
[PubMed - indexed for MEDLINE]
6.

Feasibility of simultaneous integrated boost IMRT (SIB-IMRT) for castration-resistant prostate cancer.

Hakariya T, Obata S, Igawa T, Sakai H.

Anticancer Res. 2014 Aug;34(8):4261-5.

PMID:
25075056
[PubMed - indexed for MEDLINE]
7.

Early stage prostate cancer: biochemical recurrence after treatment.

Zanatta DA, Andrade RJ, Pacagnan EF, München LW, Assumpção RA, Mercante VC, Simonetti GM.

Int Braz J Urol. 2014 Mar-Apr;40(2):137-45. doi: 10.1590/S1677-5538.IBJU.2014.02.02.

PMID:
24856480
[PubMed - indexed for MEDLINE]
Free Article
8.

Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate cancer.

Swisher-McClure S, Mitra N, Woo K, Smaldone M, Uzzo R, Bekelman JE.

Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):103-12. doi: 10.1016/j.ijrobp.2014.01.050.

PMID:
24725694
[PubMed - indexed for MEDLINE]
9.

Changes in patterns of practice for prostate cancer radiotherapy in Italy 1995-2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society.

Pegurri L, Buglione M, Girelli G, Guarnieri A, Meattini I, Ricardi U, Mangoni M, Gabriele P, Bellavita R, Krengli M, Bonetta A, Cagna E, Bunkheila F, Borghesi S, Signor M, Di Marco A, Bertoni F, Stefanacci M, Gatta R, De Bari B, Magrini SM.

Tumori. 2014 Jan-Feb;100(1):31-7. doi: 10.1700/1430.15812.

PMID:
24675488
[PubMed - indexed for MEDLINE]
10.

Biologically effective dose and definitive radiation treatment for localized prostate cancer: treatment gaps do affect the risk of biochemical failure.

Sanpaolo P, Barbieri V, Genovesi D.

Strahlenther Onkol. 2014 Aug;190(8):732-8. doi: 10.1007/s00066-014-0642-0. Epub 2014 Mar 4.

PMID:
24589919
[PubMed - indexed for MEDLINE]
11.

Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.

Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, Aird EG, Bottomley D, Huddart RA, Jose CC, Matthews JH, Millar JL, Murphy C, Russell JM, Scrase CD, Parmar MK, Sydes MR.

Lancet Oncol. 2014 Apr;15(4):464-73. doi: 10.1016/S1470-2045(14)70040-3. Epub 2014 Feb 26.

PMID:
24581940
[PubMed - indexed for MEDLINE]
Free Article
12.

Detection of radiorecurrent prostate cancer using diffusion-weighted imaging and targeted biopsies.

Rud E, Baco E, Lien D, Klotz D, Eggesbø HB.

AJR Am J Roentgenol. 2014 Mar;202(3):W241-6. doi: 10.2214/AJR.12.10483.

PMID:
24555620
[PubMed - indexed for MEDLINE]
13.

Optimal local control and tolerability of three-dimensional conformal radiation therapy in prostate cancer: a single institutional experience of dose escalation in 125 patients.

Ferrera G, Caminiti G, Grillo A, Alongi F, Evangelista G, Greco E, Cucchiara T, Bono M, Mortellaro G, Cirrincione A, Dalia F, Iacoviello G, Caputo V, Midiri M, Sciumè F.

Tumori. 2013 Nov-Dec;99(6):676-81. doi: 10.1700/1390.15455.

PMID:
24503790
[PubMed - indexed for MEDLINE]
14.

Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.

Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M 3rd, Gottschalk A.

Radiat Oncol. 2014 Feb 2;9:42. doi: 10.1186/1748-717X-9-42.

PMID:
24484652
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.

Spratt DE, Zumsteg ZS, Ghadjar P, Kollmeier MA, Pei X, Cohen G, Polkinghorn W, Yamada Y, Zelefsky MJ.

BJU Int. 2014 Sep;114(3):360-7. doi: 10.1111/bju.12514. Epub 2014 Jan 22.

PMID:
24447404
[PubMed - indexed for MEDLINE]
16.

Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - initial results of the PLATIN 3 Trial.

Katayama S, Habl G, Kessel K, Edler L, Debus J, Herfarth K, Sterzing F.

BMC Cancer. 2014 Jan 14;14:20. doi: 10.1186/1471-2407-14-20.

PMID:
24422782
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer.

Ohashi T, Yorozu A, Saito S, Momma T, Nishiyama T, Yamashita S, Shiraishi Y, Shigematsu N.

Radiat Oncol. 2014 Jan 9;9:13. doi: 10.1186/1748-717X-9-13.

PMID:
24401540
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Long-term outcomes of dynamic conformal arc irradiation combined with neoadjuvant hormonal therapy in Japanese patients with T1c-T2N0M0 prostate cancer: case series study.

Ikeda I, Mizowaki T, Norihisa Y, Takayama K, Kamba T, Inoue T, Nakamura E, Kamoto T, Ogawa O, Hiraoka M.

Jpn J Clin Oncol. 2014 Feb;44(2):180-5. doi: 10.1093/jjco/hyt197. Epub 2013 Dec 29.

PMID:
24379210
[PubMed - indexed for MEDLINE]
Free Article
19.

Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer.

Yamamoto S, Fujii Y, Masuda H, Urakami S, Saito K, Kozuka T, Oguchi M, Fukui I, Yonese J.

Qual Life Res. 2014 Jun;23(5):1641-50. doi: 10.1007/s11136-013-0603-6. Epub 2013 Dec 13.

PMID:
24338068
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Hypofractionated intensity-modulated simultaneous integrated boost and image-guided radiotherapy in the treatment of high-risk prostate cancer patients: a preliminary report on acute toxicity.

Valeriani M, Carnevale A, Osti MF, Minniti G, De Sanctis V, Agolli L, Bracci S, Enrici RM.

Tumori. 2013 Jul-Aug;99(4):474-9. doi: 10.1700/1361.15097.

PMID:
24326835
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk